Efavirenz/emtricitabine/tenofovir
| Combination of | |
|---|---|
| Efavirenz | non-nucleoside reverse transcriptase inhibitor |
| Emtricitabine | nucleoside analog reverse transcriptase inhibitor |
| Tenofovir disoproxil | nucleotide analog reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Atripla, Viraday, others |
| Other names | tenofovir disoproxil fumarate/emtricitabine/efavirenz |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| (verify) | |
Efavirenz/emtricitabine/tenofovir, sold under the brand name Atripla among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[6][5] It contains efavirenz, emtricitabine, and tenofovir disoproxil.[6][5] It can be used by itself or together with other antiretroviral medications.[6] It is taken by mouth.[4][5][6]
Common side effects include headache, trouble sleeping, sleepiness, and unsteadiness.[4] Serious side effects may include high blood lactate levels, psychiatric symptoms, and enlargement of the liver.[4] It should not be used in children.[6] If used during the first trimester of pregnancy harm to the baby may occur.[4]
Efavirenz/emtricitabine/tenofovir was approved for medical use in the United States in 2006,[4][7] and in the European Union in 2007.[5] It is on the World Health Organization's List of Essential Medicines.[8] Efavirenz/emtricitabine/tenofovir is available as a generic medication.[9][10]
- ^ a b "TGA eBS - Product and Consumer Medicine Information Licence".
- ^ "Efavirenz / emtricitabine / tenofovir (Atripla) Use During Pregnancy". Drugs.com. 27 July 2018. Retrieved 31 March 2020.
- ^ "Atripla 600 mg/200 mg/245 mg film coated tablets - Summary of Product Characteristics (SmPC)". (emc). 2 March 2020. Archived from the original on 10 August 2020. Retrieved 31 March 2020.
- ^ a b c d e f Cite error: The named reference
Atripla FDA labelwas invoked but never defined (see the help page). - ^ a b c d e "Atripla EPAR". European Medicines Agency (EMA). 7 July 2008. Retrieved 31 March 2020.
- ^ a b c d e World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 160. hdl:10665/44053. ISBN 9789241547659.
- ^ "Drug Approval Package: Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) NDA #021937". U.S. Food and Drug Administration (FDA). 13 December 2006. Archived from the original on 27 August 2015. Retrieved 25 September 2021.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Office of Generic Drugs 2018 Annual Report". U.S. Food and Drug Administration (FDA). 28 January 2021. Archived from the original on 26 September 2019. Retrieved 25 September 2021.
- ^ "Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.